LimmaTech Biologics is a technology company.
LimmaTech Biologics has raised $36.0M across 1 funding round.
LimmaTech Biologics has raised $36.0M in total across 1 funding round.
LimmaTech Biologics AG is a clinical-stage Swiss biopharmaceutical company developing next-generation vaccines against antimicrobial-resistant pathogens and sexually transmitted infections using proprietary glycoengineering, protein glycosylation, and bioconjugation technologies.[1][2][3] It targets severe microbial diseases like shigellosis, Staphylococcus aureus infections, Neisseria gonorrhoeae, Chlamydia, and Candida, serving global health needs in low- and middle-income countries and hospitals through its proprietary pipeline and partnerships with GSK and Valneva.[2][4][6] The company solves the growing threat of antimicrobial resistance (AMR) by advancing self-adjuvanting, multi-antigen vaccines, with recent positive interim Phase I/II data for its Shigella4V (S4V) candidate against diarrheal disease in infants, demonstrating strong growth momentum via clinical trials and in-licensing deals.[1][4][6]
LimmaTech Biologics emerged as a spin-off from GlycoVaxyn AG, which GSK acquired in February 2015 after a two-year collaboration, transferring glycoengineering and protein glycosylation technologies to LimmaTech.[1] Founded in Switzerland with headquarters in Schlieren, Zurich, the company has built on this legacy since 2015 under an exclusive R&D agreement with GSK, expanding into proprietary programs while retaining about 35 employees and $7.4 million in revenue.[1][3] Key pivotal moments include in-licensing the Shigella bioconjugate vaccine from GSK for Phase I/II trials, securing the LBT-SA7 toxoid vaccine from AbVacc for Phase I studies against S. aureus, and partnerships with Valneva, marking early traction in combating AMR and STIs.[4][6]
LimmaTech rides the global AMR epidemic and rising STIs, where pathogens like S. aureus and Shigella drive untreatable infections, especially in vulnerable populations.[2][3][5] Timing is critical amid post-pandemic vaccine tech momentum and regulatory pushes for rapid biopharma innovation, with market forces like hospital-acquired resistance and diarrheal deaths in low-income regions favoring scalable bioconjugates.[1][4][6] It influences the ecosystem by pioneering game-changing solutions via GSK-Valneva ties, advancing Swiss biotech leadership, and filling gaps in multi-antigen vaccines for reinfection-prone diseases.[2][5]
LimmaTech is poised for milestone readouts from Shigella4V Phase I/II and LBT-SA7 Phase I trials, potentially unlocking Phase III advancement and broader partnerships amid escalating AMR needs.[1][6] Trends like toxoid innovations and enzyme bioconjugation will shape its path, expanding the pipeline to more STIs and resistant bugs while leveraging GSK's manufacturing scale.[3][6] Its influence may evolve from niche spin-off to key player in global vaccine equity, delivering transformative impact as clinical successes compound.[2][5] This positions LimmaTech as a vital force in biopharma's fight against microbial threats, building directly on its technology heritage.
LimmaTech Biologics has raised $36.0M in total across 1 funding round.
LimmaTech Biologics's investors include Adjuvant Capital.
LimmaTech Biologics has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $36.0M Series A | Adjuvant Capital |